

NON-HEPARIN ANTICOAGULANTS

Supporting information

This guideline has been prepared with reference to the following:

Cuker A, Arepally GM, Chong BH et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia. *Blood Adv.* 2018;2: 3360–92

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC30482768/>

Linkins LA, Dans AL, Moores LK, et al. Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest* 2012;141:495S-530S

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278058/>

Watson H, Davidson S, Keeling D. Guidelines on the diagnosis and management of heparin induced thrombocytopenia: second edition, 2012

<http://www.b-s-h.org.uk/guidelines/guidelines/diagnosis-and-management-of-heparin-induced-thrombocytopenia-second-edition/>

IV infusion of danaparoid sodium influences the clinical outcome?

Danaparoid sodium, along with lepirudin and argatroban, are anticoagulants that substitute for heparin in heparin-induced thrombocytopenia (HIT) (Comunale, 2004).

A retrospective comparison of danaparoid and lepirudin (Farner, 2001) found similar efficacy but a smaller risk of bleeding associated with danaparoid (2.5% of 126 patients vs 10.4% of 175 patients).

In a randomised trial comparing danaparoid and dextran sulphate (Chong, 2001), resolution of thrombosis, on the basis of daily clinical assessment, was considered superior with danaparoid.

An outcomes analysis (treatment period plus 3 months) of 1478 patients (Magnani, 2006) found that 83.8% survived, 63.7% suffered no or minor adverse effects and 20.1% experienced serious but non-fatal adverse events.

Chong BH, Gallus AS, Cade JF, et al. Prospective randomised open-label comparison of danaparoid with dextran 70 in the treatment of heparin-induced thrombocytopenia with thrombosis: a clinical outcome study. *Thromb Haemost* 2001;86:1170-5

Comunale ME, Van Cott EM. Heparin-induced thrombocytopenia. *Int Anesthesiol Clin* 2004;42:27-43

Farner B, Eichler P, Kroll H, et al. A comparison of danaparoid and lepirudin in heparin-induced thrombocytopenia. *Thromb Haemost* 2001;85:950-7

Magnani HN, Gallus A. Heparin-induced thrombocytopenia (HIT). A report of 1478 clinical outcomes of patients treated with danaparoid (Orgaran) from 1982 to mid-2004. *Thromb Haemost* 2006;95:967-81

Evidence Level: IV

Last amended February 2023
Last reviewed November 2023